Tumor-Infiltrating Lymphocytes Activate Immune Response to Metastatic Breast Cancer

Elisa Becze, BA, ELS, Editor


More than two-thirds of patients with hormone receptor–positive metastatic breast cancer respond to personalized immunotherapy with tumor-infiltrating lymphocytes and more than half of those treated experience measurable tumor shrinkage, according to study findings published in the Journal of Clinical Oncology.

View Article @ voice.ons.org

ONS Voice Articles

Dive into a rich source of oncology nursing expertise with ONS articles.

View All Voice Articles